Drug Conjugates with Polyunsaturated Fatty Acids

Drug Delivery in Oncology: From Basic Research to Cancer Therapy

Volumn 3, Issue , 2011, Pages 1323-1357

  Seitz, Joshua ^a   Ojima, Iwao ^b  

^a UNIVERSITY OF VERMONT   (United States)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Cancer; Chemotherapy; Cytotoxic agent; Docosahexaenoic acid; Doxorubicin; Drug conjugate; Gp60; Human serum albumin; Paclitaxel; Polyunsaturated fatty acid; Targeted drug delivery; Taxoid; Tumor xenograft

Indexed keywords

EID: 84880004636     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527634057.ch41     Document Type: Chapter

References (122)

1. Desai, N., Yao, Z., Trieu, V., Soon-Shoing, P., Dykes, D., and Noker, P. (2003) Evidence of greater tumor and red cell partitioning and superior antitumor activity of cremophor free nanoparticle paclitaxel (ABI-007) compared to taxol. Breast Cancer Res. Treat., 82 (Suppl. 1), S83, Abstract 348.
2. Ibrahim, N.K., Desai, N., Legha, S., Soon-Shiong, P., Theriault, R.L., Rivera, E., Esmaeli, B., Ring, S.E., Bedikian, A., Hortobagyi, G.N., and Ellerhorst, J.A. (2002) Phase I and pharmacokinetic study of ABI-007, a cremophor-free, protein-stabilized nanoparticle formulation of paclitaxel. Clin. Cancer Res., 8, 1038-1044.
3. Desai, N., Trieu, V., Yao, Z., Louie, L., Ci, S., Yang, A., Tao, C., De, T., Beals, B., Dykes, D., Noker, P., Yao, R., Labao, E., Hawkins, M., and Soon-Shiong, P. (2006) Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin. Cancer Res., 12, 1317-1324.
4. Berquin, I.M., Edwards, I.J., and Chen, Y.Q. (2008) Multi-targeted therapy of cancer by omega-3 fatty acids. Cancer Lett., 269, 363-367.
5. Colquhoun, A.M., Miyake, J.A., and Benadiba, M. (2009) Fatty acids, eicosanoids and cancer. Nutr. Ther. Metabol., 27, 105-112.
6. Pownall, H.J. and Hamilton, J. (2003) Energy translocation across cell membranes and membrane models. Acta Physiol. Scand., 178, 357-365.
7. Hirsch, D., Stahl, A., and Lodish, H.F. (1998) A family of fatty acid transporters conserved from mycobacterium to man. Proc. Natl. Acad. Sci. USA, 95, 8625-8629.
8. Veerkamp, J.H. and Zimmerman, A.W. (2001) Fatty acid-binding proteins of nervous tissue. J. Mol. Neurosci., 16, 133-142.
9. Thumser, A.E., Tsai, J., and Storch, J. (2001) Collision-mediated transfer of long-chain fatty acids by neural tissue fatty acid-binding proteins (FABP): studies with fluorescent analogs. J. Mol. Neurosci., 16, 143-150.
10. Marszalek, J.R., Kitidis, C., Dararutana, A., and Lodish, H.F. (2004) Acyl-CoA synthetase 2 overexpression enhances fatty acid internalization. J. Biol. Chem., 279, 23882-23891.
11. Schley, P.D., Brindley, D.N., and Field, C.J. (2007) (n-3) PUFA alter raft lipid composition and decrease epidermal growth factor receptor levels in lipid rafts of human breast cancer cells. J. Nutr., 137, 548-553.
12. Foster, L.J., De Hoog, C.L., and Mann, M. (2003) Unbiased quantitative proteomics of lipid rafts reveals high specificity for signaling factors. Proc. Natl. Acad. Sci. USA, 100, 5813-5818.
13. Hardman, W.E. (2004) (n-3) fatty acids and cancer therapy. J. Nutr., 134, 3427S-3430S.
14. Dommels, Y.E., Haring, M.M., Keenstra, N.G., Alink, G.M., van Bladeren, P.J., and van Ommen, B. (2003) The role of cyclooxygenase in n-6 and n-3 poly unsaturated fatty acid mediated effects on cell proliferation, PGE2 synthesis and cytotoxicity in human colorectal carcinoma cell lines. Carcinogenesis, 24, 385-392.
15. Rose, D.P. and Connolly, J.M. (2000) Regulation of tumor angiogenesis by dietary fatty acids and eicosanoids. Nutr. Cancer, 37, 119-127.
16. Calder, P.C., Yaqoob, P., Thies, F., Wallace, F.A., and Miles, E.A. (2002) Fatty acids and lymphocyte functions. Br. J. Nutr., 87, S31-S48.
17. Brown, M.D., Hart, C.A., Gazi, E., Bagley, S., and Clarke, N.W. (2006) Promotion of prostatic metastatic migration towards human bone marrow stoma by omega 6 and its inhibition by omega 3 PUFAs. Br. J. Cancer, 94, 842-853.
18. McCarthy, M.F. (1996) Fish oil may impede tumour angiogenesis and invasiveness by down-regulating protein kinase C and modulating eicosanoid production. Med. Hypotheses, 46, 107-115.
19. Masoodi, M., Mir, A.A., Petasis, N.A., Serhan, C.N., and Nicolaou, A. (2008) Simultaneous lipidomic analysis of three families of bioactive lipid mediators leukotrienes, resolvins, protectins and related hydroxyl-fatty acids by liquid chromatography/electrospray ionization tandem mass spectrometry. Rapid Commun. Mass Spectrom., 22, 75-83.
20. Kroetz, D.L. and Zeldin, D.C. (2002) Cytochrome P450 pathways of arachidonic acid metabolism. Curr. Opin. Lipidol., 13, 273-283.
21. Sauer, L.A. and Dauchy, R.T. (1992) The effect of omega-6 and omega-3 fatty acids on 3H-thymidine incorporation in hepatoma 7288CTC perfused in situ. Br. J. Cancer, 66, 297-303.
22. Damtew, B.S. and Spagnuolo, P.J. (1997) Tumor cell-endothelial cell interactions: evidence for roles for lipoxygenase products of arachidonic acid in metastasis. Prostagland. Leukotr. Essent. Fat. Acid., 56, 295-300.
23. Calder, P.C. and Grimble, R.F. (2002) Polyunsaturated fatty acids, inflammation and immunity. Eur. J. Clin. Nutr., 87, S14-S19.
24. Sauer, L.A.B., Blask, D.E., and Dauchy, R.T. (2007) Dietary factors and growth and metabolism in experimental tumors. J. Nutr. Biochem., 18, 637-649.
25. Sauer, L.A., Dauchy, R.T., Blask, D.E., Krause, J.A., Davidson, L.K., and Dauchy, E.M. (2005) Eicosapentaenoic acid suppresses cell proliferation in MCF-7 human breast cancer xenografts in nude rats via a pertussis toxin-sensitive transduction pathway. J. Nutr., 135, 2124-2129.
26. Serhan, C.N., Hong, S., Gronert, K., Colgan, S.P., Devchand, P.R., Mirick, G., and Moussignac, R.L. (2002) Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J. Exp. Med., 196, 1025-1037.
27. Clevers, H. (2004) At the crossroads of inflammation and cancer. Cell, 118, 671-674.
28. Sauer, L.A., Dauchy, R.T., and Blask, D.E. (2000) Mechanism for the antitumor and anticachectic effects of n-3 fatty acids. Cancer Res., 60, 5289-5295.
29. Crawford, M.G., Galli, C., Visioli, F., Renaud, S., Simopoulos, A.P., and Spector, A.A. (2000) Role of plant-derived omega-3 fatty acids in human nutrition. Ann. Nutr. Metabol., 44, 263-265.
30. Rose, D.P. and Connolly, J.M. (1990) Effects of fatty acids and inhibitors of eicosanoid synthesis on the growth of a human breast cancer cell line in culture. Cancer Res., 50, 7139-7144.
31. Badawi, A.F.A. and Archer, M.C. (1998) Effect of hormonal status on the expression of the cyclooxygenase 1 and 2 genes and prostaglandin synthesis in rat mammary glands. Prostaglandins Other Lipid Mediat., 56, 167-181.
32. Singh, J., Hamid, R., and Reddy, B.S. (1997) Dietary fat and colon cancer: modulation of cyclooxygenase-2 by types and amount of dietary fat during the postinitiation stage of colon carcinogenesis. Cancer Res., 57, 3465-3470.
33. Von Schacky, C., Kiefl, R., Marcus, A.J., Broekman, M.J., and Kaminski, W.E. (1993) Dietary n - 3 fatty acids accelerate catabolism of leukotriene B4 in human granulocytes. Biochim. Biophys. Acta, 1166, 20-24.
34. Calviello, G., Di Nicuolo, F., Gragnoli, S., Piccioni, E., Serini, S., Maggiano, N., Tringali, G., Navarra, P., Ranelletti, F.O., and Palozza, P. (2004) n-3 PUFAs reduce VEGF expression in human colon cancer cells modulating the COX-2/PGE2 induced ERK-1 and -2 and HIF-1a induction pathway. Carcinogenesis, 25, 2303-2320.
35. Larsson, S.C., Kumlin, M., Ingelman-Sundberg, M., and Wolk, A. (2004) Dietary long-chain n-3 fatty acids for the prevention of cancer: a review of potential mechanisms. Am. J. Clin. Nutr., 79, 935-945.
36. Sivaraman, V.S., Wang, H., Nuovo, G.J., and Malbon, C.C. (1997) Hyperexpression of mitogen-activated kinase in human breast cancer. J. Clin. Invest., 99, 1478-1483.
37. Boucher, M.-J., Morisset, J., Vachon, P.H., Reed, J.C., Laine, J., and Rivard, N. (2000) MEK/ERK signaling pathway regulates the expression of Bcl2, BclXL and Mcl-1 and promotes survival of human pancreatic cancer cells. J. Cell. Biochem., 79, 355-369.
38. Smally, K.S.M. (2003) A pivotal role for ERK in the oncogenic behavior of malignant melanoma. Int. J. Cancer, 104, 527-532.
39. Bos, J.L. (1989) Ras oncogenes in human cancer: a review. Cancer Res., 49, 4682-4689.
40. Schwartz, S.A.H., Hernandez, A., and Mark Evers, B. (1999) The role of NF-kappaB/IkappaB proteins in cancer: implications for novel treatment strategies. Surg. Oncol., 8, 143-153.
41. Bharti, A.C. and Aggarwal, B.B. (2004) Ranking the role of RANK ligand in apoptosis. Apoptosis, 9, 677-690.
42. Novak, T.E., Babcock, T.A., Jho, D.H., Helton, W.S., and Espat, N.J. (2003) NF-kappa B inhibition by omega-3 fatty acids modulates LPS-stimulated macrophage TNF-alpha transcription. Am. J. Physiol., 284, L84-L85.
43. Kersten, S., Desvergne, B., and Wahli, W. (2000) Roles of PPARS in health and disease. Nature, 405, 421-424.
44. Ho, T.-C., Chen, S.-L., Yang, Y.-C., Liao, C.-L., Cheng, H.-C., and Tsao, Y.-P. (2006) PEDF induces p53-mediated apoptosis through PPAR gamma signaling in human umbilical vein endothelial cells. Cardiovasc. Res., 76, 213-223.
45. Bonofiglio, D., Aquila, S., Catalano, S., Gabriele, S., Belmonte, M., Middea, E., Qui, H., Morelli, C., Gentile, M., Maggiolini, M., and Ando, S. (2006) Peroxisome proliferator-activated receptor-γ activates p53 gene promoter binding to the nuclear factor-γB sequence in human MCF7 breast cancer cells. Mol. Endocrinol., 20, 3083-3092.
46. Zand, H., Rhimipour, A., Bakhshayesh, M., Shafiee, M., Nour Mohammadi, I., and Salimi, S. (2007) Involvement of PPAR-γ and p53 in DHA-induced apoptosis in Reh cells. Mol. Cell. Biochem., 304, 71-77.
47. Diep, Q.N., Touyz, R.M., and Schiffrin, E.L. (2000) Docosahexaenoic acid, a peroxisome proliferator-activated receptor-alpha ligand, induces apoptosis in vascular smooth muscle cells by stimulation of p38 mitogen-activated protein kinase. Hypertension, 36, 851-855.
48. Tuller, E.R., Brock, A.L., Yu, H., Lou, J.R., Benbrook, D.M., and Ding, W.-Q. (2009) PPARa signaling mediates the synergistic cytotoxicity of clioquinol and docosahexaenoic acid in human cancer cells. Biochem. Pharmacol., 77, 1480-1486.
49. Berger, A., Roberts, M.A., and Hoff, B. (2006) How dietary arachidonicand docosahexaenoic-acid rich oils differentially affect the murine hepatic transcriptome. Lipids Health Dis., 5, 10.
50. Fan, Y.Y., Spencer, T.E., Wang, N., Moyer, M.P., and Chapkin, R.S. (2003) Chemopreventive n-3 fatty acids activate RXR-alpha in colonocytes. Carcinogenesis, 24, 1541-1548.
51. Aktas, H. and Halperin, J.A. (2004) Translational regulation of gene expression by n-3 fatty acids. J. Nutr., 136, 2487S-2491S.
52. Reddy, B.S., Simi, B., Patel, N., Alaiaga, C., and Rao, C.V. (1996) Effect of amount and types of dietary fat on intestinal bacterial 7 alpha-dehydroxylase and phosphatidylinositol-specific phospholipase C and colonic mucosal diacylglycerol kinase and PKC activities during stages of colon tumor promotion. Cancer Res., 56, 2314-2320.
53. Fang, J.L., Vaca, C.E., Valsta, L.M., and Mutanen, M. (1996) Determination of DNA adducts of alonaldehyde in humans: effects of dietary fatty acid composition. Carcinogenesis, 17, 1035-1040.
54. Cosgrove, J.P., Church, D.F., and Pryor, W.A. (1987) The kinetics of the autoxidation of polyunsaturated fatty acids. Lipids Health Dis., 22, 299-304.
55. Abou-el-Ela, S.H., Prasse, K.W., Farrell, R.L., Carroll, R.W., Wade, A.E., and Bunce, O.R. (1989) Effects of d, l-2-difluoromethylornithine and indomethacin on mammary tumor promotion in rats fed high n-3 and/or n-6 fat diets. Cancer Res., 49, 1434-1440.
56. Chajes, V., Sattler, W., Stranzl, A., and Kostner, G.M. (1995) Influence of n-3 fatty acids on the growth of human breast cancer cells in vitro: relationship to peroxides and vitamin E. Breast Cancer Res. Treat., 34, 199-212.
57. Arita, K., Kobuchi, H., Utsumi, T., Takehara, Y., Akiyama, J., Horton, A.A., and Utsumi, K. (2001) Mechanism of apoptosis in HL-60 cells induced by n-3 and n-6 polyunsaturated fatty acids. Biochem. Pharmacol., 62, 821-828.
58. Grimm, H., Mayer, K., Mayser, P., and Eigenbrodt, E. (2002) Regulatory potential of n-3 fatty acids in immunological and inflammatory processes. Br. J. Nutr., 87, S59-S67.
59. Rose, D.P. and Connolly, J.M., (1999) Omega-3 fatty acids as cancer chemopreventive agents. Pharmacol. Ther., 83, 217-244.
60. Zhuo, Z., Zhang, L., Mu, Q., Lou, Y., Gong, Z., Shi, Y., Ouyang, G., and Zhang, Y. (2009) The effect of combination treatment with docosahexaenoic acid and 5-fluorouracil on the mRNA expression of apoptosis-related genes, including the novel gene BCL2L12, in gastric cancer cells. In Vitro Cell. Dev. Biol. Anim., 45, 69-74.
61. Yamamoto, D., Kiyozuka, Y., Adachi, Y., Takada, H., Hioki, K., and Tsubura, A. (1999) Synergistic action of apoptosis induced by eicosapentaenoic acid and TNP-470 on human breast cancer cells. Breast Cancer Res. Treat., 55, 149-160.
62. Nakagawa, H., Yamamoto, D., Kiyozuka, Y., Tsuta, K., Uemura, Y., Hioki, K., Tsutsui, Y., and Tsubura, A. (2000) Effects of genistein and synergistic action in combination with eicosapentaenoic acid on the growth of breast cancer cell lines. J. Cancer Res. Clin. Oncol., 126, 448-454.
63. Menendez, J.A., Ropero, S., del Mar Barbacid, M., Montero, S., Solanas, M., Escrich, E., Cortes-Funes, H., and Colmer, R. (2001) Synergistic interaction between vinorelbine and gamma-linolenic acid in breast cancer cells. Eur. J. Cancer, 37, 402-413.
64. Menedez, J.A., del Mar Barbacid, M., Montero, S., Sevilla, E., Escrich, E., Solanas, M., Cortes-Funes, H., and Colomer, R. (2001) Effects of gamma-linolenic acid and oleic acid on paclitaxel cytotoxicity in human breast cancer cells. Eur. J. Cancer, 37, 402-413.
65. Hardman, W.E.M., Moyer, M.P., and Cameron, I.L. (2000) Dietary fish oil sensitizes A549 lung xenografts to doxorubicin chemotherapy. Cancer Lett., 151, 145-151.
66. Shao, Y., Pardini, L., and Pardini, R.S. (1995) Dietary menhaden oil enhances mitomycin C antitumor activity toward human mammary carcinoma MX-1. Lipids, 30, 1035-1045.
67. DeGraffenried, L.A., Friedrichs, W.E., Fulcher, L., Fernandes, G., and Silva, J.M. (2003) Eicosapentaenoic acid restores tamoxifen sensitivity in breast cancer cells with high Akt activity. Ann. Oncol., 14, 969-970.
68. Rowinsky, E.K. (1997) The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu. Rev. Med., 48, 353-374.
69. Wani, M.C., Taylor, H.L., and Wall, M.E. (1971) Plasnt antitumor agents VI. The isolation and structure of taxol: a novel antileukemic and antitumour agent from Taxus brevifolia. J. Am. Chem. Soc., 93, 2325-2327.
70. McGuirem, W.P., Rowinsky, E.K., Rosenshein, N.B., Grumbine, F.C., Ettinger, D.S., Armstrong, D.K., and Donehower, R.C. (1989) Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann. Intern. Med., 111, 273-279.
71. Schiff, P.B., Fant, J., and Horwitz, S.B. (1980) Taxol stabilizes microtubules in mouse fibroblast cells. Proc. Natl. Acad. Sci. USA, 77, 1561-1565.
72. Jordan, M.A., Toso, R.J., Thrower, D., and Wilson, L. (1993) Mechanism of mitotic block and inhibition of cell proliferation by Taxol at low concentrations. Mol. Biol. Cell, 10, 947-949.
73. Hennenfent, K.L. and Govindan, R., (2006) Novel formulations of taxanes: a review. Old wine in a new bottle? Ann. Oncol., 17, 735-749.
74. Xie, Z., Guan, H., Chen, X., Lu, C., Chen, L., Hu, X., Shi, Q., and Jing, X. (2007) A novel polymer-paclitaxel conjugate based on amphiphilic triblock copolymer. J. Control. Release, 117, 210-216.
75. Wang, Y., Xin, D., Liu, K., Zhu, M., and Xiang, J. (2009) Heparin-paclitaxel conjugates as drug delivery system: synthesis, self-assembly property, drug release, and antitumor activity. Bioconjug. Chem., 20, 2214-2221.
76. Ojima, I., Chen, J., Sun, L., Borell, C.P., Wang, T., Miller, M.L., Lin, S., Geng, X., Kuznetsova, L., Qu, C., Gallager, D., Zhao, X., Zanardi, I., Xia, S., Horwitz, S.B., Mallen-St. Clair, J., Guerriero, J.L., Bar-Sagi, D., Veith, J.M., Pera, P., and Bernacki, R.J. (2008) Design, synthesis, and biological evaluation of new-generation taxoids. J. Med. Chem., 51, 3203-3221.
77. Tsao, Y.P., Russo, A., Nyamuswa, G., Silber, R., and Liu, L.F. (1993) Interaction between replication forks and topoisomerase I-DNA cleavable complexes: studies in a cell-free SV40 DNA replication system. Cancer Res., 53, 5908-5914.
78. Tanizawa, A., Fujimori, A., Fujimori, Y., and Pommier, Y. (1994) Comparison of topoisomerase I inhibition, DHA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J. Natl. Cancer Inst., 86, 836-842.
79. Wang, Y., Li, L., Jiang, W., and Larrick, J.W. (2005) Synthesis and evaluation of a DHA and 10-hydroxycamptotecin conjugate. Bioorg. Med. Chem., 13, 5592-5599.
80. Myers, C.E. and Chabner, B.A. (1990) Cancer Chemotherapy - Principles and Practice, Lippincott, Philadelphia, PA.
81. Dorr, R.T. and Von Hoff, D.D. (1994) Cancer Chemotherapy Handbook, 2nd edn, Appleton & Lange, Norwalk, CT.
82. Fornari, F.A., Randolph, J.K., Yalowich, J.C., Ritke, M.K., and Gewitz, D.A. (1994) Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells. Mol. Pharmacol., 45, 649-656.
83. Wang, Y., Li, L., Jiang, W., Yang, Z., and Zhang, Z. (2006) Synthesis and preliminary antitumor activity evaluation of a DHA and doxorubicin conjugate. Bioorg. Med. Chem. Lett., 16, 2974-2977.
84. Kaneko, T., Willner, D., Monkovic, I., Knipe, J.O., Braslawsky, G.R., Greenfield, R.S., and Vyas, D.M. (1991) New hydrazone derivatives of adriamycin and their immunoconjugates - a correlation between acid stability and cytotoxicity. Bioconjug. Chem., 2, 133-141.
85. Huan, M.-L., Zhou, S.-Y., Teng, Z.-H., Zhang, B.-L., Liu, X.-Y., Wang, J.-P., and Mei, Q.-B. (2009) Conjugation with a-linolenic acid improves cancer cell uptake and cytotoxicity of doxorubicin. Bioorg. Med. Chem. Lett., 19, 2579-2584.
86. Mammoto, T., Mukai, M., Mammoto, A., Yamanaka, Y., Hayashi, Y., Mashimo, T., Kishi, Y., and Nakamura, H. (2002) Intravenous anesthetic, propofol inhibits invasion of cancer cells. Cancer Lett., 184, 165-170.
87. Siddiqui, R.A., Zerouga, M., Wu, M., Castillo, A., Harvey, K., Zaloga, G.P., and Stillwell, W. (2005) Anticancer properties of propofol-docosahexaenoate and propofol-eicosapentaenoate of breast cancer cells. Breast Cancer Res., 7, R645-R654.
88. Harvey, K.A., Xu, Z., Whitley, P., Davisson, V.J., and Siddiqui, R.A. (2010) Characterization of anticancer properties of 2,6- diisopropylphenol-docasahexaenoate and analogues in breast cancer cells. Biorg. Med. Chem., 10, 1866-1874.
89. Schobert, R., Biersack, B., Knauer, S., and Ocker, M. (2008) Conjugates of the fungal cytotoxin illudin M with improved tumour specificity. Bioorg. Med. Chem. Lett., 16, 8592-8597.
90. Senzer, N., Arsenau, J., Rchards, D., Berman, B., MacDonald, J.R., and Smith, S. (2005) Irofulven demonstrates clinical activity against metastatic hormone-refractory prostate cancer in a phase 2 single-agent trial. Am. J. Clin. Oncol., 28, 36-42.
91. Alexandre, J., Raymond, E., Karci, M.O., Brain, E.C., Lokiec, F., Kahatt, C., Faivre, S., Yovin, A., Goldwasser, F., Smith, S.L., MacDonald, J.R., Misset, J.L., and Cvitkovic, E. (2004) Phase I and pharmacokinetic study of irofulven administered weekly or biweekly in advanced solid tumor patients. Clin. Cancer Res., 10, 3377-3385.
92. Anel, A., Halmos, T., Torres, J.M., Pineiro, A., Antonakis, K., and Uriel, J. (1990) Cytotoxicity of chlorambucil and chlorambucil-fatty acid conjugates against human lymphomas and normal human peripheral blood lymphocytes. Biochem. Pharmacol., 40, 1193-1200.
93. Esteban, C., Geuskens, M., and Ureil, J. (1991) Activation of an alpha-fetoprotein (AFP)/receptor autocrine loop in HT-29 human colon carcinoma cells. Int. J. Cancer, 49, 425-430.
94. Amiel, S.A., Stewart, J.F., Earl, H.M., Knight, R.K., and Rubens, R.D. (1984) Adriamycin and mitomycin C as initial chemotherapy for advanced breast cancer. Eur. J. Cancer Clin. Oncol., 20, 631-634.
95. Krauss, S., Sonoda, T., and Solomon, A. (1979) Treatment of advanced gastrointestinal cancer with 5-fluorouracil and mitomycin C. Cancer, 43, 1598-1603.
96. Roos, W.P. and Kaina, B. (2006) DNA damage-induced cell death by apoptosis. Trends Mol. Med., 12, 440-450.
97. Shikano, M., Onimura, K., Fukai, Y., Hori, M., Fukazawa, H., Mizuno, S., Yazawa, K., and Uehara, Y. (1998) 1a-docosahexaenoyl mitomycin C: a novel inhibitor of protein tyrosine kinase. Biochem. Biophys. Res. Commun., 248, 858-863.
98. Peters, G.J., van der Wilt, C.L., van Moorsel, C.J.A., Kroep, J.R., Bergman, A.M., and Ackland, S.P. (2000) Basis for effective combination cancer chemotherapy with antimetabolites. Pharmacol. Ther., 87, 227-253.
99. '-dexoy-5-fluorouridine as prodrugs for the selective delivery of 5-fluorouracil to tumor cells. Biochem. Pharmacol., 44, 149-155.
100. Zhang, Y.-X., Dai, G.F., Wang, L., and Tao, J.-C. (2007) Synthesis and cytotoxicity of novel fatty acid-nucleoside conjugates. Bioorg. Med. Chem. Lett., 17, 1613-1615.
101. Barnwarth, B., Labat, I., Moride, Y., and Schaeverbeke, T. (1994) Methotrexate in theumatoid arthritis: an update. Drugs, 47, 25-50.
102. Kinsky, S.C., Loader, J.E., and Hashimoto, K. (1987) Inhibition of cell proliferation by putative metabolites and non-degradable analogs of methotrexate-gamma-dimyristoylphosphatidylethanolamine. Biochim. Biophys. Acta, 917, 211-218.
103. Zerouga, M., Stillwell, W., and Jenski, L.J. (2002) Synthesis of a novel phosphatidylcholine conjugated to docosahexaenoic acid and methotrexate that inhibits cell proliferation. Anti-Cancer Drugs, 13, 301-311.
104. Tannock, I.F. (1989) Principles of cell proliferation: cell kinetics in Cancer: Principle and Practice of Oncology, (eds V.T. DeVita Jr., S. Hellman, and S.A. Rosenberg), 3rd edn, Lippincott, Philadelphia, PA, pp. 3-13.
105. Bradley, M.O., Webb, N.L., Anthony, F.H., Devanesan, P., Witman, P.A., Hemamalini, S., Chander, M.C., Baker, S.D., He, L., Horwitz, S.B., and Swindell, C.S. (2001) Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel. Clin. Cancer Res., 7, 3229-3258.
106. Sparreboom, A., Wolff, A.C., Verweig, J., Zabelina, Y., van Zomeren, D.M., McIntire, G.L., Swindell, C.S., Donehower, R.C., and Baker, S.D. (2003) Disposition of docosahexaenoic acid-paclitaxel, a novel taxane, in blood: in vitro and clinical pharmacokinetic studies. Clin. Cancer Res., 9, 151-159.
107. Sparreboom, A., van Zuylen, L., Brouwer, E., Loos, W.J., de Bruijn, P., Gelderblom, H., Pillay, M., Nooter, K., Stoter, G., and Verweig, J. (1999) Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res., 59, 1454-1457.
108. Wolff, A.C., Donehower, R.C., Carducci, M.K., Carducci, M.A., Brahmer, J.R., Zabelina, Y., Bradley, M.O., Anthony, F.H., Swindell, C.S., Witman, P.A., Webb, N.L., and Baker, S.D. (2003) Phase I study of docosahexaenoic acid-paclitaxel: a taxane-fatty acid conjugate with a unique pharmacology and toxicity profile. Clin. Cancer Res., 9, 3589-3597.
109. Browder, T., Butterfield, C.E., Kraling, B.M., Shi, B., Marshall, B., O'Reilly, M.S., and Folkman, J. (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res., 60, 1878-1886.
110. Fracasso, P.M., Picus, J., Wildi, J.D., Goodner, S.A., Creekmore, A.N., Gao, F., Govindan, R., Ellis, M.J., Tan, B.R., Linette, G.P., Fu, C.H.H., Pentikis, H.S., Zumbrun, S.C., Egorin, M.J., and Bellet, R.E. (2009) Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, Taxoprexin®, in resistant solid tumor malignancies. Cancer Chemother. Pharmacol., 63, 451-458.
111. Smith, R.E., Brown, A.M., Mamounas, E.P., Anderson, S.J., Lembersky, B.C., Atkins, J.H., Shibata, H.R., Baez, L., DeFusco, P.A., Divila, E., Tipping, S.J., Bearden, J.D., and Thirlwell, M.P. (1999) Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26. J. Clin. Oncol., 17, 3403-3411.
112. Bellet, R., Carducci, M., Petrylak, D., Kasimis, B., Irwin, D., Modiano, M., Manour, R., Axelrod, R., and Doukas, M. (2004) Phase II study of DHA-paclitaxel (TXP) as first line chemotherapy in patients with hormone refractory prostate cancer (HRPC). Proc. Am. Soc. Clin. Oncol., 22, 4657.
113. Johnston, S.R.D., Houston, S., Jones, A., Evans, T.R., and Schacter, L. (2004) Efficacy of DHA-paclitaxel (TXP) for the second-line treatment of breast cancer. Proc. Am. Soc. Clin. Oncol., 22, 65.
114. Jacobs, A., Planting, A., Ferry, D., Michell, E., Evans, T.R., Wilke, H., Hochster, H., Knuth, A., Schacter, L., and Donehower, R. (2003) Efficacy of DHA-paclitaxel (TXP) in pancreatic cancer. Proc. Am. Soc. Clin. Oncol., 21, 2981.
115. Jones, R.J., Hawkins, R.E., Eatock, M.M., Ferry, D.R., Eskens, F.A.L.M., Wilke, H., and Evans, T.R.J. (2008) A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma. Cancer Chemother. Pharmacol., 61, 435-441.
116. Schacter, L.P., Bukowski, R.M., Carducci, M.A., Donehower, R., Dunlop, D., Evans, T.R., Gilby, E., and Johnston, S. (2004) Safety and efficacy of DHA-Paclitaxel (TXP) in non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol., 22, 7111.
117. Payne, M., Ellis, P., Dunlop, D., Ranson, M., Danson, S., Schacter, L., and Talbot, D. (2006) DHA-paclitaxel (Taxoprexin) as first-line treatment in patients with stage IIIB or IV non-small cell lung cancer: report of a phase II open-label multicenter trial. J. Thorac. Oncol., 1, 984-990.
118. Modiano, M.R., Houston, S., Savage, P., Price, C., Schacter, L., and Gilby, E. (2003) Efficacy of DHA-paclitaxel (TXP) in malignant melanoma. Proc. Am. Soc. Clin. Oncol., 21, 2891.
119. Harries, M., O'Donnell, A., Scurr, M., Reade, S., Cole, C., Judson, I., Greystoke, A., Twelves, C., and Kaye, S. (2004) Phase I/II study of DHA-paclitaxel in combination with carboplatin in patients with advanced malignant solid tumors. Br. J. Cancer, 91, 1651-1655.
120. Vredenburg, M.R., Ojima, I., Veith, J., Pera, P., Kee, K., Cabral, F., Sharma, A., Kanter, P., and Bernacki, R.J. (2001) Effects of orally active taxanes on P-glycoprotein modulation and colon and breast carcinoma drug resistance. J. Natl. Cancer Inst., 93, 1234-1245.
121. Ferlini, C., Distefano, M., Pignatelli, F., Lin, S., Riva, A., Bombardelli, E., Mancuso, S., Ojima, I., and Scambia, G. (2000) Antitumor activity of novel taxanes that act as cytotoxic agents and P-glycoprotein inhibitors at the same time. Br. J. Cancer, 83, 1762-1768.
122. Kuznetsova, L., Chen, J., Sun, L., Wu, X., Pepe, A., Veith, J.M., Pera, P., Bernacki, R.J., and Ojima, I. (2006) Synthesis and evaluation of novel fatty acid-second-generation taxoid conjugates as promising anticancer agents. Bioorg. Med. Chem. Lett., 16, 974-977.